Paclitaxel nanoencapsulated

N/A

Report date: 2026/05/26 20:00:28

Base Information

Drug NamePaclitaxel nanoencapsulated
Drug Alias NamePaclitaxel in Polyethyloxazoline PolymerFID-007 (紫杉醇聚乙基恶唑啉纳米颗粒)Nanoencapsulated Paclitaxel FID-007PEOX-based Polymer Encapsulated Paclitaxel FID-007Nanoencapsulated paclitaxel +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitorsAngiogenesis inhibitorsMitosis inhibitors +[6] 
TargetsTubulinPlatelet-derived growth factorApoptosis regulator Bcl-2
Therapy Area/IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAnp Technologies
China Registration ClassN/A

Develop Information

Active CompaniesFulgent Genetics IncUniversity Of Southern CaliforniaFulgent Pharma Llc
Inactive CompaniesN/A
Active IndicationsSolid tumoursLung NeoplasmsHead and Neck Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A